OHSU Knight Cancer Institute

IRB #

STUDY00019078

Title

[NCI CIRB] S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III

Principal Investigator

Alexandra Zimmer

Study Purpose

To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab–based HER-2 targeted therapy.

Medical Condition(s)

Metastatic Her-2+ Breast Cancer

Eligibility Criteria

1- metastatic breast HER-2 breast cancer and continuing/initiating trastuzumab targeted therapy

2- Must be at increased risk for cardiotoxicity

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

108 weeks

Minors Included

No

Contact

Knight Cancer Institute Clinical Trials
trials@ohsu.edu
503 494-1080

Sponsor

SWOG

Recruitment End

09/30/2028

Compensation Provided

No